Cognition Therapeutics (CGTX) News Today $0.46 -0.05 (-9.78%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cognition Therapeutics Reports Promising Q3 2024 ResultsNovember 14 at 2:16 PM | markets.businessinsider.comCognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical UpdateNovember 14 at 4:11 AM | finanznachrichten.deCognition Therapeutics sees cash runway into 2Q25November 14 at 4:11 AM | markets.businessinsider.comCognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical UpdateNovember 13, 2024 | globenewswire.comCognition Therapeutics to Present at Zacks SCR Life Sciences Investor ForumNovember 12, 2024 | globenewswire.comHC Wainwright Reiterates Buy Rating for Cognition Therapeutics (NASDAQ:CGTX)November 8, 2024 | americanbankingnews.comPositive Buy Rating Reaffirmed for Cognition Therapeutics Amid Promising Alzheimer’s Drug DataNovember 5, 2024 | markets.businessinsider.comCognition Therapeutics (CGTX) Gets a Buy from OppenheimerNovember 5, 2024 | markets.businessinsider.comNovember’s Small-Cap Treasures: 3 Stocks Poised for Growth (CGTX)Three promising small-cap stocks, poised for growth in healthcare, cybersecurity, and renewable energy, offer compelling investment opportunities for November.November 4, 2024 | marketbeat.comCognition Therapeutics’ Mixed Phase II Results Justify Hold Rating Amid Uncertain Broad EfficacyOctober 31, 2024 | markets.businessinsider.comCognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTADOctober 31, 2024 | globenewswire.comCognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTADOctober 29, 2024 | globenewswire.comAnalyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTADOctober 23, 2024 | globenewswire.comCognition Therapeutics releases new episode of ‘Conversations’ podcastOctober 23, 2024 | markets.businessinsider.comCognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)October 22, 2024 | globenewswire.comCognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ...October 9, 2024 | finance.yahoo.comCognition Therapeutics Will Participate in the Roth Healthcare Opportunities ConferenceOctober 2, 2024 | markets.businessinsider.comCognition Therapeutics Will Participate in the Roth Healthcare Opportunities ConferenceOctober 2, 2024 | globenewswire.comCognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common DementiaOctober 1, 2024 | globenewswire.comCognition Therapeutics (NASDAQ:CGTX) Stock, Insider Trading ActivitySeptember 26, 2024 | benzinga.comCognition Therapeutics (NASDAQ:CGTX) Stock, Short Interest ReportSeptember 25, 2024 | benzinga.comXBiotech Inc. (4XB.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comHealios K.K. (4593.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comFrost & Sullivan Grants the Global Cognitive Impairment Digital Therapy Innovation Award to BRAINAUSeptember 20, 2024 | markets.businessinsider.comGain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024September 19, 2024 | markets.businessinsider.comCognition Therapeutics to Participate in Upcoming September 2024 Investor ConferencesSeptember 3, 2024 | globenewswire.comCognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s DiseaseAugust 22, 2024 | markets.businessinsider.comCognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's DiseaseAugust 22, 2024 | globenewswire.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Q1 2024 Earnings Call TranscriptAugust 12, 2024 | msn.comCognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call TranscriptAugust 11, 2024 | seekingalpha.comCognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical UpdateAugust 8, 2024 | globenewswire.comB. Riley Securities Downgrades Cognition Therapeutics (CGTX)August 7, 2024 | msn.comCognition Therapeutics to Report Second Quarter 2024 Financial ResultsAugust 5, 2024 | globenewswire.comCantor Fitzgerald Downgrades Cognition Therapeutics (CGTX)July 31, 2024 | msn.comCognition Therapeutics (NASDAQ:CGTX) Rating Lowered to Neutral at Cantor FitzgeraldCantor Fitzgerald downgraded shares of Cognition Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday.July 30, 2024 | marketbeat.comCognition Therapeutics Down 39% on Alzheimer's Drug Study NewsJuly 30, 2024 | marketwatch.comPittsburgh-founded company's clinical trial demonstrates 'consistent improvement' in Alzheimer's patientsJuly 30, 2024 | bizjournals.comCognition Therapeutics Reports Improvement In Cognitive Outcomes In Phase 2 SHINE Study In AD.July 30, 2024 | markets.businessinsider.comCognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer’s diseaseJuly 30, 2024 | msn.comCognition’s Alzheimer’s study shows improvement in cognitive outcomesJuly 30, 2024 | msn.comWhy Is Cognition Therapeutics (CGTX) Stock Down 33% Today?July 29, 2024 | investorplace.comCognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's PatientsJuly 29, 2024 | globenewswire.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of "Buy" from BrokeragesShares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have received an average recommendation of "Buy" from the six analysts that are currently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12July 27, 2024 | marketbeat.comSOFTWeb Adaptive I.T. Solutions (SOFTWEB.AT)July 26, 2024 | finance.yahoo.com(RWLD.DU)July 26, 2024 | finance.yahoo.comCognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024July 26, 2024 | globenewswire.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest Up 15.2% in JuneCognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 208,100 shares, an increase of 15.2% from the June 15th total of 180,700 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 147,000 shares, the short-interest ratio is presently 1.4 days.July 16, 2024 | marketbeat.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Buy" from BrokeragesCognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six analysts that are covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price target among bJuly 2, 2024 | marketbeat.comResults from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAICJuly 2, 2024 | globenewswire.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest UpdateCognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 180,700 shares, a decline of 14.2% from the May 31st total of 210,600 shares. Currently, 0.5% of the company's stock are sold short. Based on an average trading volume of 144,300 shares, the short-interest ratio is currently 1.3 days.July 1, 2024 | marketbeat.com Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip? Click Here to learn how to get in now >>> CGTX Media Mentions By Week CGTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGTX News Sentiment▼0.210.56▲Average Medical News Sentiment CGTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGTX Articles This Week▼81▲CGTX Articles Average Week Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bolt Biotherapeutics News Today MiNK Therapeutics News Today Avalo Therapeutics News Today Daré Bioscience News Today Elevation Oncology News Today SCYNEXIS News Today Oramed Pharmaceuticals News Today Coherus BioSciences News Today Cidara Therapeutics News Today Werewolf Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGTX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
